These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33522024)

  • 1. Omalizumab in chronic inducible urticaria: A real-life study of efficacy, safety, predictors of treatment outcome and time to response.
    Yu M; Terhorst-Molawi D; Altrichter S; Hawro T; Chen YD; Liu B; Song XT; Zhao ZT; Maurer M
    Clin Exp Allergy; 2021 May; 51(5):730-734. PubMed ID: 33522024
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria.
    Dortas Junior S; Azizi G; Valle S
    Ann Allergy Asthma Immunol; 2020 Oct; 125(4):486-487. PubMed ID: 32544531
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
    Farrah G; Stevenson B; Lie K; Brusch A
    Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
    Skander D; Allenova A; Maurer M; Kolkhir P
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
    Belbezier A; Boccon-Gibod I; Bouillet L
    Eur J Dermatol; 2021 Feb; 31(1):86-87. PubMed ID: 33772528
    [No Abstract]   [Full Text] [Related]  

  • 6. Addition of omalizumab to antihistamine treatment in chronic urticaria: A real-world study in China.
    Chen YD; Maurer M; Yu M; Tu P; Zhao ZT
    Ann Allergy Asthma Immunol; 2020 Aug; 125(2):217-219. PubMed ID: 32371240
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
    Salman A; Ergun T; Gimenez-Arnau AM
    J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
    [No Abstract]   [Full Text] [Related]  

  • 8. Characteristics of patients with chronic spontaneous urticaria showing early and complete responses to omalizumab.
    Cho YT; Fu KT; Yang CW; Chu CY
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):394-395. PubMed ID: 34102302
    [No Abstract]   [Full Text] [Related]  

  • 9. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.
    Vollono L; Piccolo A; Lanna C; Esposito M; Bavetta M; Campione E; Bianchi L; Diluvio L
    Drug Des Devel Ther; 2019; 13():3181-3186. PubMed ID: 31564834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab in chronic inducible urticaria: A retrospective, real-life study.
    Fialek M; Dezoteux F; Le Moing A; Karimova E; Ramdane N; Pape E; Azib-Meftah S; Staumont-Sallé D
    Ann Dermatol Venereol; 2021 Dec; 148(4):262-265. PubMed ID: 34247853
    [No Abstract]   [Full Text] [Related]  

  • 11. Omalizumab retreatment in patients with chronic spontaneous urticaria: a systematic review of published evidence.
    Tonacci A; Nettis E; Asero R; Rossi O; Tontini C; Gangemi S
    Eur Ann Allergy Clin Immunol; 2020 May; 52(3):100-103. PubMed ID: 32108461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab.
    Ensina LF; Arruda LK; Campos RA; Criado RF; Rodrigues Valle S; Melo JM; Oliveira JC; Dortas JS; Cusato-Ensina AP; Camelo-Nunes IC; Agondi RC
    J Investig Allergol Clin Immunol; 2020 Apr; 30(2):145-147. PubMed ID: 31762438
    [No Abstract]   [Full Text] [Related]  

  • 13. Omalizumab for chronic urticaria in children younger than 12 years.
    Al-Shaikhly T; Rosenthal JA; Ayars AG; Petroni DH
    Ann Allergy Asthma Immunol; 2019 Aug; 123(2):208-210.e2. PubMed ID: 31082483
    [No Abstract]   [Full Text] [Related]  

  • 14. The response to treatment in chronic spontaneous urticaria depends on how it is measured.
    Weller K; Church MK; Metz M; Hawro T; Ohanyan T; Staubach P; Maurer M
    J Allergy Clin Immunol Pract; 2019; 7(6):2055-2056.e4. PubMed ID: 30731179
    [No Abstract]   [Full Text] [Related]  

  • 15. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
    Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
    Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of four types of chronic urticaria with anti-IgE omalizumab in the same patient.
    Nettis E; Di Leo E; Calogiuri G; Foti C; Macchia L
    Ann Allergy Asthma Immunol; 2019 Mar; 122(3):336-337. PubMed ID: 30529714
    [No Abstract]   [Full Text] [Related]  

  • 17. Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment.
    Asero R; Ferrucci S; Casazza G; Marzano AV; Cugno M
    Allergy; 2019 Aug; 74(8):1561-1563. PubMed ID: 30801715
    [No Abstract]   [Full Text] [Related]  

  • 18. Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria.
    Spekhorst LS; van den Reek JMPA; Knulst AC; Röckmann H
    Allergy; 2019 Jun; 74(6):1185-1187. PubMed ID: 30593687
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria.
    Di Leo E; Calogiuri G; Macchia L; Nettis E
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):300-302. PubMed ID: 29802908
    [No Abstract]   [Full Text] [Related]  

  • 20. COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases.
    Ayhan E; Öztürk M; An İ; Bekçİbaşi M
    Int J Dermatol; 2021 Feb; 60(2):253-254. PubMed ID: 33332576
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.